JPRN-jRCT2031210449进行中（未招募）2 期
Assessment of Safety, Tolerability, and Efficacy of LY3372689 in Early Symptomatic Alzheimer's Disease - I9X-MC-MTAE
Masaki Takeshi0 个研究点目标入组 330 人开始时间: 2021年11月24日最近更新:
适应症
试验速览
- 阶段
- 2 期
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 330
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- >= 60age old 至 <= 85age old（—）
- 性别
- All
入选标准
- •Gradual and progressive change in memory function reported by participants or informants for >= 6 months
- •-MMSE score of 22 to 30 (inclusive) at baseline
- •-CDR global score of 0.5 to 1.0 (inclusive), with a memory box score >=0.5.
- •-Meet 18F flortaucipir positron emission tomography (PET) scan (central analysis) criteria
- •-Have a study partner who will provide written informed consent to participate
排除标准
- •-Contraindication to MRI or PET scans
- •-Have known allergies to LY3372689, related compounds, or any components of the formulations
研究者
相似试验
进行中（未招募）
1 期
Donanemab in Early Symptomatic Alzheimer’s DiseaseEUCTR2020-000077-25-PLEli Lilly and Company1,800
已完成
2 期
A Study of LY3303560 in Participants With Early Symptomatic Alzheimer's DiseaseAlzheimer's DiseaseJPRN-jRCT2080223944Eli Lilly Japan K.K.360
招募中
1 期
Donanemab in Early Symptomatic Alzheimer’s DiseaseEUCTR2020-000077-25-NLEli Lilly and Company1,736
已完成
3 期
Assessment of Safety, Tolerability, and Efficacy of Donanemab in Early Symptomatic Alzheimer*s DiseaseEarly Symptomatic Alzheimer's DiseaseAlzheimersenile psychosisNL-OMON52785Eli Lilly27
进行中（未招募）
1 期
Assessment of Safety, Tolerability, and Efficacy of (LY3372689) in Participants With Alzheimer’s DiseaseAlzheimer DiseaseMedDRA version: 20.0Level: PTClassification code 10012271Term: Dementia Alzheimer's typeSystem Organ Class: 10029205 - Nervous system disordersEUCTR2021-000170-29-PLEli Lilly and Company340